RhumbLine Advisers
RLAY icon

RhumbLine Advisers’s Relay Therapeutics RLAY Stock Holding History

RhumbLine Advisers’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.51M Buy
241,076
+24,143
+11% +$350K ﹤0.01% 1527
2026
Q1 		$2.16M Buy
216,933
+1,192
+0.6% +$10.7K ﹤0.01% 1813
2025
Q4 		$1.83M Sell
215,741
-1,851
-0.9% -$13.2K ﹤0.01% 1922
2025
Q3 		$1.14M Sell
217,592
-4,261
-2% -$16.2K ﹤0.01% 2176
2025
Q2 		$768K Buy
221,853
+47,728
+27% +$142K ﹤0.01% 2382
2025
Q1 		$456K Buy
174,125
+2,681
+2% +$10.5K ﹤0.01% 2636
2024
Q4 		$706K Buy
171,444
+13,532
+9% +$73.6K ﹤0.01% 2445
2024
Q3 		$1.12M Sell
157,912
-5,983
-4% -$44.7K ﹤0.01% 2207
2024
Q2 		$1.07M Buy
163,895
+7,508
+5% +$51.3K ﹤0.01% 2204
2024
Q1 		$1.3M Buy
156,387
+4,942
+3% +$48.2K ﹤0.01% 2113
2023
Q4 		$1.67M Sell
151,445
-1,732
-1% -$14.6K ﹤0.01% 2002
2023
Q3 		$1.29M Buy
153,177
+4,771
+3% +$51.3K ﹤0.01% 2070
2023
Q2 		$1.86M Buy
148,406
+12,846
+9% +$160K ﹤0.01% 1945
2023
Q1 		$2.23M Buy
135,560
+6,696
+5% +$120K ﹤0.01% 1745
2022
Q4 		$1.93M Buy
128,864
+10,305
+9% +$197K ﹤0.01% 1805
2022
Q3 		$2.65M Buy
118,559
+8,122
+7% +$178K ﹤0.01% 1617
2022
Q2 		$1.85M Buy
110,437
+34,999
+46% +$750K ﹤0.01% 1800
2022
Q1 		$2.26M Buy
75,438
+5,437
+8% +$132K ﹤0.01% 1752
2021
Q4 		$2.15M Buy
70,001
+8,260
+13% +$261K ﹤0.01% 1839
2021
Q3 		$1.95M Buy
61,741
+2,876
+5% +$96.8K ﹤0.01% 1922
2021
Q2 		$2.15M Buy
58,865
+8,583
+17% +$283K ﹤0.01% 1916
2021
Q1 		$1.74M Buy
50,282
+9,902
+25% +$430K ﹤0.01% 1973
2020
Q4 		$1.68M Buy
40,380
+3,771
+10% +$170K ﹤0.01% 1931
2020
Q3 		$1.56M Buy
+36,609
New +$1.4M ﹤0.01% 1808

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

RhumbLine Advisers's RLAY Position: Q2 2026 in Review

RhumbLine Advisers increased its Relay Therapeutics (RLAY) stake by 11% in Q2 2026, buying an estimated $350K and bringing the position to 241,076 shares worth $4.51M. The position accounts for ﹤0.01% of the portfolio, ranked #1527.

RhumbLine Advisers first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • RhumbLine Advisers held 241,076 shares of Relay Therapeutics worth $4.51M as of Q2 2026.
  • RhumbLine Advisers bought 24,143 Relay Therapeutics shares in Q2 2026, an estimated $350K.
  • Relay Therapeutics made up ﹤0.01% of RhumbLine Advisers's portfolio in Q2 2026, its #1527 holding.
  • RhumbLine Advisers first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.